Reflecting on 2021 – a year of progress
As we bid farewell to another challenging year, we reflect on our work with partners and colleagues in 2021.
We had a fantastic time at #RAREfest22 with @camraredisease.
It was great to see the #LifeScience and rare diseas… https://t.co/nb4o0FuOSh
LifeArc appoints first Chief Operating Officer
Richard Godfrey has joined LifeArc as its first Chief Operating Officer (COO). The new role will strengthen…
LifeArc participates in Series A funding round for company developing pioneering new gene therapies for neurodegenerative diseases
Helping to progress an innovative gene therapy platform from the bench to a stage where it is progressing closer to the clinic.
LifeArc unveils new strategy and £1.3 billion spend to drive life-changing science
Aims to transform the way diseases such as motor neurone disease are prevented, identified and treated.
New approach provides potential vaccine and treatment for Alzheimer’s
An antibody-based treatment and protein-based vaccine reduced Alzheimer’s symptoms in mouse models of the disease.
Advanced diagnosis for patients with rare conditions
This week, results from the 100,000 Genomes Project showed that whole genome sequencing improves the diagnosis of…
10 new data-driven health companies selected for KQ Labs accelerator programme
10 innovative start-up companies working at the interface of biomedical and data science are to receive personalised…
LifeArc’s technology transfer team supports MRC researchers in making cryo-electron microscopy even sharper
Reimagining the grid manufacturing process.
LifeArc invests in company developing personalised drug and digital combination treatments
LifeArc and partners announce a £13 million financing deal in Closed Loop Medicine to enable the company to develop further and faster.